This panel discussion provides an in-depth discussion on stratifying risk, navigating prognoses, and personalized treatment for breast cancer, featuring insights from experts Prof. Sotiriou and Prof. Nogueira, led by Prof. Cardoso.
Prof. Sotiriou presentation:
01:27 -Â Discussion on the epidemiology of breast cancer, including the number of new cases and deaths in 2020, and the impact of improved screening techniques.
02:17 -Â Explanation of the diagnosis and staging process for breast cancer, including tumor biopsy and biomarker assessment.
06:53 -Â Overview of the MonarchE study and its findings on the benefits of adding masitinib to endocrine therapy for breast cancer treatment.
09:09 -Â Recommendations for HER2 positive early breast cancer treatment, including surgery and chemotherapy options.
12:09Â - Discussion on the treatment approach for triple-negative breast cancer, including the use of chemotherapy and immunotherapy.
Prof. Nogueira presentation:
0:50 -Â The importance of the classification of breast cancer into hormone receptor, HER2, and triple-negative categories, which has been guiding treatment decisions for over 25 years.
1:45 -Â The need for personalized selection of systemic therapy options, including targeted therapy, immunotherapy, and chemotherapy, based on tumor characteristics and previous treatments.
5:02 -Â Discussion of the relevance of HER2 expression and the need to classify patients as 1+ or 2+ for potential treatment benefits.
8:46 -Â The importance of a multidisciplinary approach, including psychologists, physiotherapists, nutritionists, and social workers, to support patients through treatment and improve their quality of life.
9:21 -Â The crucial role of palliative care in improving the quality of life and symptom management for metastatic breast cancer patients, recommending its early introduction.
Discussion
1:01 - Olaparib and BRCA Mutations
2:10 - Sequencing Treatments for BRCA Mutations
5:22 - Metastatic Setting and Treatment Sequencing
7:34 - ER+ and BRCA Mutations
9:14 - Assessing Risk in Early Setting
11:51 - Dealing with Primary and Metastatic Tumors